Alpha-O Peptides

Pre-clinical

Zurich, SwitzerlandFounded 2016aopeptides.com

Alpha-O Peptides AG is a private Swiss biotech firm specializing in the development of advanced vaccine and drug delivery platforms centered on Self-Assembling Protein Nanoparticles (SAPN). The company has built a robust patent estate with filings in major global markets, protecting its core technologies for antigen display, vaccine applications, and immunostimulatory delivery. Its business model revolves around technology development and out-licensing to pharmaceutical and biotechnology partners for further clinical development and commercialization.

Founded

2016

Focus

Vaccines

AI Company Overview

Technology Platform

Proprietary Self-Assembling Protein Nanoparticle (SAPN) technology for designing nanoscale protein structures used as versatile platforms for vaccine antigen display, integrated adjuvant delivery, and encapsulation of immunostimulatory nucleic acids.

Funding History

Total raised: $6.4M

Seed$3.2MUndisclosedJan 15, 2023

Seed$3.2MVenture KickNov 15, 2022

Opportunities

The company's modular SAPN platform presents significant opportunities in next-generation vaccine development, particularly for difficult-to-target pathogens and in therapeutic oncology.

The integration of adjuvant functions and nucleic acid delivery within a single nanoparticle could address key unmet needs in vaccine stability, potency, and rapid response capability, making it attractive for partnership.

Risk Factors

Key risks include the pre-clinical nature of all technology, requiring significant validation; reliance on a licensing business model without guaranteed partners; intense competition from large pharma and well-funded biotechs; and the ongoing need for financing to sustain operations and advance the platform.

Competitive Landscape

Alpha-O Peptides competes with large vaccine developers (GSK, Merck) with proprietary adjuvant systems and numerous biotech platform companies (e.g., Vaxxinity, IMV Inc.). Its differentiation hinges on the unique combination of self-assembly, built-in adjuvant activity (flagellin), and nucleic acid encapsulation within a single, protein-based nanoparticle platform protected by a broad patent portfolio.